CanSino begins phase I studies on Ad5-nCoV

CanSino begins  phase I studies  on Ad5-nCoV

CanSino Bio and its collaborators at the Academy of Military Medical Sciences’ Institute of Biotechnology won a quick Chinese regulatory approval to start human testing of their recombinant coronavirus vaccine, the company said.

CanSino’s candidate, called Ad5-nCoV, uses its adenovirus-based viral vector vaccine platform. The technology helped the company to secure a Chinese regulatory approval for its Ebola vaccine.

According to CanSino, preclinical results showed that the vaccine can induce a strong immune response in animal models, with a good safety profile.

The new phase 1 trial will be conducted in healthy adults 18 to 60 years of age in Wuhan, China.

Straight Talk

View More